Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Manganese sulfate - Medesis Pharma

Next Previous
X
Search
Drug Profile

Manganese sulfate - Medesis Pharma

Alternative Names: NanoManganese®; NP-02; NP02 - NanoManganese®

Latest Information Update: 07 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medesis Pharma
  • Class Heavy metals
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Radiation injuries; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 26 Oct 2023 Medesis Pharma terminates a phase II trial in COVID-2019 infections in Brazil (PO) because of the insufficient recruitment in the trial due to lower COVID cases (NCT05451654)
  • 04 Feb 2022 Phase-II clinical trials in COVID-2019 infections in Brazil (PO) (NCT05451654)
  • 06 Apr 2021 Medesis Pharma plans to request for Temporary Authorization for Use (ATU) for SARS-COV-2 acute respiratory disease in France in Q4 of 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top